 |
|
Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?
Eirini Theodoraki, Eleni Orfanoudaki, Kalliopi Foteinogiannopoulou, Evangelia Legaki, Maria Gazouli, Ioannis E. Koutroubakis
Intest Res. 2021;19(4):461-467. Published online 2020 Aug 18 DOI: https://doi.org/10.5217/ir.2020.00042
|
|
Citations to this article as recorded by
 Identifying risk factors of anti‐TNF induced skin lesions and other adverse events in paediatric patients with inflammatory bowel disease
Karen van Hoeve, Debby Thomas, Tom Hillary, Ilse Hoffman, Erwin Dreesen
Journal of Pediatric Gastroenterology and Nutrition.2024; 78(1): 95. CrossRef Comparison of the Pharmacokinetics of CT-P13 Between Crohn’s Disease and Ulcerative Colitis
Eun Soo Kim, Sung Kook Kim, Dong Il Park, Hyo Jong Kim, Yoo Jin Lee, Ja Seol Koo, Eun Sun Kim, Hyuk Yoon, Ji Hyun Lee, Ji Won Kim, Sung Jae Shin, Hyung Wook Kim, Hyun-Soo Kim, Young Sook Park, You Sun Kim, Tae Oh Kim, Jun Lee, Chang Hwan Choi, Dong Soo Ha
Journal of Clinical Gastroenterology.2023; 57(6): 601. CrossRef Effect of antinuclear antibodies on pharmacokinetics of anti-TNF therapy in patients with inflammatory bowel disease
Eirini Theodoraki, Eleni Orfanoudaki, Kalliopi Foteinogiannopoulou, Nikolaos-Panagiotis Andreou, Maria Gazouli, Ioannis E. Koutroubakis
International Journal of Colorectal Disease.2022; 37(3): 639. CrossRef Can Anti-Tumor Necrosis Factor Agents Be Discontinued in Patients with Inflammatory Bowel Disease?
Jihye Park, Jae Hee Cheon
Gut and Liver.2021; 15(5): 641. CrossRef Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review
Ji Young Chang, Jae Hee Cheon
Precision and Future Medicine.2021; 5(4): 151. CrossRef
|